Before taking Canakinumab(ILARIS)

Requires vigilance for infections, hypersensitivity, and immunizations.

Risk Mitigation in Immunomodulatory Therapy

Serious Infections: Contraindicated in active infections; monitor for TB, opportunistic pathogens (e.g., aspergillosis). Discontinue if severe infection occurs.

Hypersensitivity: Immediate discontinuation for anaphylaxis or DRESS syndrome.

Immunizations: Avoid live vaccines; complete recommended vaccines pre-treatment.

Drug Interactions: Avoid concomitant TNF inhibitors (e.g., etanercept) or IL-1 blockers (e.g., anakinra) due to infection/neutropenia risks.

Pregnancy/Lactation: Limited data; consider placental transfer of IgG and infant immune risks.

Related Columns

Canakinumab(ILARIS)

Still’s Disease,Periodic Fever Syndromes

WeChat Scan
Free Inquiry

What are the Precautions for Canakinumab (Ilaris) Administration?

Canakinumab (Ilaris) is a humanized monoclonal antibody that exerts its therapeutic effect by specifically blocking the activity of interleukin-1β (IL-1β), and is primarily indicated for the treatment...

Precautions for Canakinumab

Canakinumab is a prescription drug that has been marketed in the United States and China. It is an important therapeutic drug used to treat a variety of diseases. However, the use of canakinumab requi...

Precautions for Canakinumab

Canakinumab is a human monoclonal anti-human interleukin (IL)-1β antibody used to treat a variety of immune inflammatory diseases. It can specifically bind to human IL-1β and block the interaction bet...